New pill tested for rare tumors in Real-World setting
NCT ID NCT07272512
Summary
This study is testing how well the oral medication surufatinib works for people with advanced neuroendocrine tumors in real-world medical practice. About 350 adult patients will take the pill daily, either alone or combined with other treatments, as determined by their doctors. Researchers will track how long the treatment controls tumor growth, monitor side effects, and see how it affects patients' quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huadong Hospital Affiliated to Fudan University
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Huashan Hospital Affiliated to Fudan University
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai General Hospital shanghai jiao tong university school of medicine
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.